Dr. Janice M. Mehnert
Claim this profileLaura and Isaac Perlmutter Cancer Center at NYU Langone
About Janice M. Mehnert
Education:
- Holds an MD (Doctor of Medicine).
Experience:
- Faculty member in the Department of Medicine at NYU Langone Health.
- Serves as the Associate Director of Clinical Research at the Perlmutter Cancer Center.
- Recognized internationally for expertise in early phase clinical trials, especially in skin cancer and advanced cancers.
- Plays a key role in the leadership team at Perlmutter Cancer Center.
- Specializes in skin cancer and phase 1 clinical trials for advanced cancers, with efforts to expand clinical trials across multiple locations.
Area of expertise
Melanoma
Janice M. Mehnert has run 9 trials for Melanoma. Some of their research focus areas include:
Cancer
Janice M. Mehnert has run 8 trials for Cancer. Some of their research focus areas include:
Affiliated Hospitals
Laura And Isaac Perlmutter Cancer Center At NYU Langone
NYU Langone Health
Clinical Trials Janice M. Mehnert is currently running
GV20-0251
for Cancer
This is a Phase 1/2A study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.
Recruiting
1 award
Phase 1 & 2
Nivolumab
for Cancer
This phase Ib trial studies the side effects of nivolumab and to see how well it works alone and in combination with other treatments, such as ipilimumab, cabozantinib, platinum containing therapy, and fluoropyrimidine, in treating patients with autoimmune disorders and cancer that has spread from where it first started (primary site) to nearby tissue, lymph nodes, or distant parts of the body (advanced), to other places in the body (metastatic) or cannot removed by surgery (unresectable). Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib blocks certain proteins, which may help keep tumor cells from growing. It may also prevent the growth of new blood vessels that tumors need to grow. Cabozantinib is a type of tyrosine kinase inhibitor and a type of angiogenesis inhibitor. Chemotherapy drugs, such as platinum containing therapies and fluoropyrimidine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving nivolumab alone and in combination with other treatments, including ipilimumab, cabozantinib, platinum containing therapy, or fluoropyrimidine, may be safe, tolerable, and/or effective in treating patients with autoimmune disorders and advanced, metastatic, or unresectable cancer.
Recruiting
1 award
Phase 1
20 criteria
More about Janice M. Mehnert
Clinical Trial Related
5 years of experience running clinical trials · Led 18 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Janice M. Mehnert has experience with
- Nivolumab
- Ipilimumab
- Pembrolizumab
- RP1
- Trametinib
- Laboratory Biomarker Analysis
Breakdown of trials Janice M. Mehnert has run
Melanoma
Cancer
Skin Cancer
Non-Small Cell Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Janice M. Mehnert specialize in?
Janice M. Mehnert focuses on Melanoma and Cancer. In particular, much of their work with Melanoma has involved Stage IV patients, or patients who are Stage III.
Is Janice M. Mehnert currently recruiting for clinical trials?
Yes, Janice M. Mehnert is currently recruiting for 3 clinical trials in New York New York. If you're interested in participating, you should apply.
Are there any treatments that Janice M. Mehnert has studied deeply?
Yes, Janice M. Mehnert has studied treatments such as Nivolumab, Ipilimumab, Pembrolizumab.
What is the best way to schedule an appointment with Janice M. Mehnert?
Apply for one of the trials that Janice M. Mehnert is conducting.
What is the office address of Janice M. Mehnert?
The office of Janice M. Mehnert is located at: Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York 10016 United States. This is the address for their practice at the Laura and Isaac Perlmutter Cancer Center at NYU Langone.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.